Treatment Satisfaction of Patients With Advanced Non–Small-cell Lung Cancer Receiving Platinum-based Chemotherapy: Results From a Prospective Cohort Study (PERSONAL)

Visser, Sabine; Mol, Mark de; Cheung, King‐Loong; Toor, Jermo J. van; Walree, Nico C. van; Stricker, Bruno H. Ch.; Oudsten, Brenda L. Den; Aerts, Joachim

doi:10.1016/j.cllc.2018.03.003

Cited by 9 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…80% of patients would receive the same therapy again, and older patients reported higher satisfaction with therapy levels. 106 Additionally, it is found that low-grade AEs were associated with feelings about side effects subscale (continued on following page) standardize patient-reported tolerability data collection by establishing a core set of measures for health care utilization (eg, hospitalizations) and inclusion of patientreported symptomatic toxicities and functional measures. 70 How to best encode patient interpretations of tolerability within discrete item measures is an understudied question.…”

Section: Eortc Qlq-c30mentioning

confidence: 99%

Understanding Treatment Tolerability in Older Adults With Cancer

Flannery

Culakova

Canin

et al. 2021

JCO

View full text Add to dashboard Cite

Section: Eortc Qlq-c30mentioning

confidence: 99%

Understanding Treatment Tolerability in Older Adults With Cancer

Flannery

Culakova

Canin

et al. 2021

JCO

View full text Add to dashboard Cite

“…A549 and SK-MES-1 cells were seeded at 5,000 cells per well in 96-well plates. After achieving 80% confluence, cells were treated with vehicle or different concentrations of cisplatin (2,4,8,12, and 16 μmol/L) for 48 h. Subsequently, the old media were removed completely, and 100 μL fresh RPIM1640 media and 10 μL CCK-8 reagent were added to each well. After 1-h incubation, plate was read at 450 nm, and IC50 was assessed using GraphPad Prism5.…”

Section: Cisplatin Treatmentmentioning

confidence: 99%

“…Currently, chemotherapy is the major strategy to treat lung cancer. Platinum-based chemotherapy has been considered as an optimal option for the management of lung cancer (2). Mechanistically, platinum-DNA adducts inhibit DNA repair, inhibiting tumor proliferation and promoting tumor cell apoptosis (3).…”

mentioning

confidence: 99%

Differences of inflammatory microenvironment and sensitive correlation to cisplatin-chemotherapy in lung adenocarcinoma and squamous cell carcinoma

2022

View full text Add to dashboard Cite

Introduction: Non-small cell lung cancer (NSCLC) is the most prevalent type of cancer worldwide and associated with high mortality rate. An effective treatment for NSCLC is urgently needed. This study aimed to investigate differences of inflammatory microenvironment and sensitive correlation to cisplatin-chemotherapy in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), thereby providing insights into the mechanisms underlying inflammation in NSCLC. Materials and methods: The resistance of A549 and SK-MES-1 cells to cisplatin treatment was determined by IC50. The migration and invasion capacity of A549 and SK-MES-1 cells was determined using migration and invasion assay kits. The apoptosis rate was evaluated. The protein expression levels of caspase-3 and Ki67 were measured by western blot. ELISA assay was used to determine the levels of inflammatory cytokines, including IL-4, IL-6, IL-8, and TNF-α. Results: Patients with LUAD showed shorter survival than LUSC patients after the chemotherapy treatment. LUAD was more resistant to cisplatin treatment, corresponding with a higher IC50 observed in A549 cells than SK-MES-1 cells. Moreover, A549 cells showed higher migration and invasion capacity and lower apoptosis rate than SK-MES-1 cells. In addition, SK-MES-1 LUAD samples showed stronger inflammation response than LUAD samples and A549 cells. Accordingly, inflammation cytokines promoted the migration and invasion of SK-MES-1 cells, whereas inhibited cell apoptosis. Conclusions: The present study suggests that LUAD is more resistant to chemotherapy and shows a stronger inflammation response than LUSC. Inflammatory cytokines could enhance the resistance of LUAD to chemotherapy and further promote tumor cell proliferation, migration, and invasion.

show abstract

“…18,19 There are few previous studies that evaluate satisfaction with treatment decisions among advanced cancer patients. 20 Visser et al 20 found that 86% of patients with advanced lung cancer indicated that they would decide to undergo the same treatment again, regardless of deterioration or improvement in quality of life. Umihara et al 21 found that among patients who had received cancer treatment, 67% of patients were satisfied with their decision, and that satisfaction was related to good patient physician communication.…”

Section: Patients and Oncologists Feel Starting The Treatment Was The Right Decisionmentioning

confidence: 99%

Patients with Metastatic Lung Cancer and Oncologists’ Views on Achievement of Treatment Goals and Making the Right Treatment Decision: A Prospective Multicenter Study

et al. 2021

View full text Add to dashboard Cite

Background Previous studies have investigated patients’ treatment goals before starting a treatment for metastatic lung cancer. Data on the evaluation of treatment goals are lacking. Aim To determine if patients with metastatic lung cancer and their oncologists perceive the treatment goals they defined at the start of systemic treatment as achieved after treatment and if in hindsight they believe it was the right decision to start systemic therapy. Design and Participants A prospective multicenter study in 6 hospitals across the Netherlands between 2016 and 2018. Following systemic treatment, 146 patients with metastatic lung cancer and 23 oncologists completed a questionnaire on the achievement of their treatment goals and whether they made the right treatment decision. Additional interviews with 15 patients and 5 oncologists were conducted. Results According to patients and oncologists, treatment goals were achieved in 30% and 37% for ‘quality of life,’ 49% and 41% for ‘life prolongation,’ 26% and 44% for ‘decrease in tumor size,’ and 44% for ‘cure’, respectively. Most patients and oncologists, in hindsight, felt they had made the right decision to start treatment and also if they had not achieved their goals (72% and 93%). This was related to the feeling that they had to do ‘something.’ Conclusions Before deciding on treatment, the treatment options, including their benefits and side effects, and the goals patients have should be discussed. It is key that these discussions include not only systemic treatment but also palliative care as effective options for doing ‘something.’

show abstract

Treatment Satisfaction of Patients With Advanced Non–Small-cell Lung Cancer Receiving Platinum-based Chemotherapy: Results From a Prospective Cohort Study (PERSONAL)

Cited by 9 publications

References 30 publications

Understanding Treatment Tolerability in Older Adults With Cancer

Understanding Treatment Tolerability in Older Adults With Cancer

Differences of inflammatory microenvironment and sensitive correlation to cisplatin-chemotherapy in lung adenocarcinoma and squamous cell carcinoma

Patients with Metastatic Lung Cancer and Oncologists’ Views on Achievement of Treatment Goals and Making the Right Treatment Decision: A Prospective Multicenter Study

Contact Info

Product

Resources

About